COSMOS Pharmaceutical Corporation

TSE:3349 Stock Report

Market Cap: JP¥515.3b

COSMOS Pharmaceutical Future Growth

Future criteria checks 2/6

COSMOS Pharmaceutical is forecast to grow earnings and revenue by 5.1% and 7% per annum respectively. EPS is expected to grow by 5.1% per annum. Return on equity is forecast to be 10.5% in 3 years.

Key information

5.1%

Earnings growth rate

5.08%

EPS growth rate

Consumer Retailing earnings growth7.8%
Revenue growth rate7.0%
Future return on equity10.47%
Analyst coverage

Good

Last updated11 Sep 2026

Recent future growth updates

Analysis Article • Jul 15

Analysts Have Been Trimming Their COSMOS Pharmaceutical Corporation (TSE:3349) Price Target After Its Latest Report

Shareholders might have noticed that COSMOS Pharmaceutical Corporation ( TSE:3349 ) filed its annual result this time...
Analysis Article • Apr 15

COSMOS Pharmaceutical Corporation (TSE:3349) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Last week, you might have seen that COSMOS Pharmaceutical Corporation ( TSE:3349 ) released its quarterly result to the...
Analysis Article • Jan 15

COSMOS Pharmaceutical Corporation (TSE:3349) Half-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year

There's been a notable change in appetite for COSMOS Pharmaceutical Corporation ( TSE:3349 ) shares in the week since...
Analysis Article • Oct 16

COSMOS Pharmaceutical Corporation Just Missed EPS By 8.0%: Here's What Analysts Think Will Happen Next

COSMOS Pharmaceutical Corporation ( TSE:3349 ) shareholders are probably feeling a little disappointed, since its...
Analysis Article • Jul 16

Here's What Analysts Are Forecasting For COSMOS Pharmaceutical Corporation (TSE:3349) After Its Annual Results

Last week, you might have seen that COSMOS Pharmaceutical Corporation ( TSE:3349 ) released its annual result to the...
Analysis Article • Apr 16

COSMOS Pharmaceutical Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Investors in COSMOS Pharmaceutical Corporation ( TSE:3349 ) had a good week, as its shares rose 8.8% to close at...

Recent updates

Analysis Article • Jul 15

Analysts Have Been Trimming Their COSMOS Pharmaceutical Corporation (TSE:3349) Price Target After Its Latest Report

Shareholders might have noticed that COSMOS Pharmaceutical Corporation ( TSE:3349 ) filed its annual result this time...
Analysis Article • Apr 15

COSMOS Pharmaceutical Corporation (TSE:3349) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Last week, you might have seen that COSMOS Pharmaceutical Corporation ( TSE:3349 ) released its quarterly result to the...
Analysis Article • Feb 16

COSMOS Pharmaceutical (TSE:3349) Seems To Use Debt Quite Sensibly

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Jan 15

COSMOS Pharmaceutical Corporation (TSE:3349) Half-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year

There's been a notable change in appetite for COSMOS Pharmaceutical Corporation ( TSE:3349 ) shares in the week since...
Analysis Article • Nov 28

Returns On Capital Signal Tricky Times Ahead For COSMOS Pharmaceutical (TSE:3349)

There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
Analysis Article • Nov 13

COSMOS Pharmaceutical (TSE:3349) Will Pay A Dividend Of ¥37.50

COSMOS Pharmaceutical Corporation's ( TSE:3349 ) investors are due to receive a payment of ¥37.50 per share on 12th of...
Analysis Article • Nov 12

Does COSMOS Pharmaceutical (TSE:3349) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Oct 27

COSMOS Pharmaceutical's (TSE:3349) Dividend Will Be ¥37.50

The board of COSMOS Pharmaceutical Corporation ( TSE:3349 ) has announced that it will pay a dividend on the 12th of...
Analysis Article • Oct 16

COSMOS Pharmaceutical Corporation Just Missed EPS By 8.0%: Here's What Analysts Think Will Happen Next

COSMOS Pharmaceutical Corporation ( TSE:3349 ) shareholders are probably feeling a little disappointed, since its...
Analysis Article • Sep 17

Some Shareholders Feeling Restless Over COSMOS Pharmaceutical Corporation's (TSE:3349) P/E Ratio

With a price-to-earnings (or "P/E") ratio of 22.8x COSMOS Pharmaceutical Corporation ( TSE:3349 ) may be sending very...
Analysis Article • Aug 15

Here's Why We Think COSMOS Pharmaceutical (TSE:3349) Is Well Worth Watching

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysis Article • Jul 16

Here's What Analysts Are Forecasting For COSMOS Pharmaceutical Corporation (TSE:3349) After Its Annual Results

Last week, you might have seen that COSMOS Pharmaceutical Corporation ( TSE:3349 ) released its annual result to the...
Analysis Article • Jul 04

Return Trends At COSMOS Pharmaceutical (TSE:3349) Aren't Appealing

To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...
Analysis Article • Jun 02

Is COSMOS Pharmaceutical (TSE:3349) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • May 17

Investor Optimism Abounds COSMOS Pharmaceutical Corporation (TSE:3349) But Growth Is Lacking

With a price-to-earnings (or "P/E") ratio of 24.7x COSMOS Pharmaceutical Corporation ( TSE:3349 ) may be sending very...
Analysis Article • Apr 16

COSMOS Pharmaceutical Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Investors in COSMOS Pharmaceutical Corporation ( TSE:3349 ) had a good week, as its shares rose 8.8% to close at...
Analysis Article • Mar 27

Should You Be Adding COSMOS Pharmaceutical (TSE:3349) To Your Watchlist Today?

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Analysis Article • Mar 11

COSMOS Pharmaceutical's (TSE:3349) Returns On Capital Not Reflecting Well On The Business

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Analysis Article • Jan 31

COSMOS Pharmaceutical Corporation's (TSE:3349) Business Is Yet to Catch Up With Its Share Price

With a price-to-earnings (or "P/E") ratio of 21.5x COSMOS Pharmaceutical Corporation ( TSE:3349 ) may be sending very...
Analysis Article • Jan 17

COSMOS Pharmaceutical Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Shareholders of COSMOS Pharmaceutical Corporation ( TSE:3349 ) will be pleased this week, given that the stock price is...
Analysis Article • Dec 25

Here's Why COSMOS Pharmaceutical (TSE:3349) Can Manage Its Debt Responsibly

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Nov 18

COSMOS Pharmaceutical's (TSE:3349) Returns On Capital Not Reflecting Well On The Business

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Analysis Article • Sep 26

We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Aug 17

An Intrinsic Calculation For COSMOS Pharmaceutical Corporation (TSE:3349) Suggests It's 41% Undervalued

Key Insights The projected fair value for COSMOS Pharmaceutical is JP¥23,011 based on 2 Stage Free Cash Flow to Equity...
Analysis Article • Aug 01

COSMOS Pharmaceutical (TSE:3349) Will Want To Turn Around Its Return Trends

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...
Analysis Article • Jun 28

Subdued Growth No Barrier To COSMOS Pharmaceutical Corporation's (TSE:3349) Price

COSMOS Pharmaceutical Corporation's ( TSE:3349 ) price-to-earnings (or "P/E") ratio of 20.7x might make it look like a...
Analysis Article • Jun 10

We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Apr 17

COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

It's been a good week for COSMOS Pharmaceutical Corporation ( TSE:3349 ) shareholders, because the company has just...
Analysis Article • Mar 16

Some Shareholders Feeling Restless Over COSMOS Pharmaceutical Corporation's (TSE:3349) P/E Ratio

With a price-to-earnings (or "P/E") ratio of 23.3x COSMOS Pharmaceutical Corporation ( TSE:3349 ) may be sending very...
Analysis Article • Feb 28

Returns On Capital At COSMOS Pharmaceutical (TSE:3349) Paint A Concerning Picture

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...

Earnings and Revenue Growth Forecasts

TSE:3349 - Analysts future estimates and past financials data (JPY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
5/31/20291,369,82136,374-63380,2158
5/31/20281,271,78834,113-2,90073,69010
5/31/20271,186,91632,103-7,90068,1629
5/31/20261,099,58332,046-11,67258,790N/A
2/28/20261,069,50231,383N/AN/AN/A
11/30/20251,042,62931,198-46259,529N/A
8/31/20251,021,94331,006N/AN/AN/A
5/31/20251,011,39030,978-85952,467N/A
2/28/20251,001,94629,440N/AN/AN/A
11/30/2024994,49527,2953,53553,314N/A
8/31/2024985,17726,089N/AN/AN/A
5/31/2024964,98924,454-63555,175N/A
2/29/2024936,70624,871N/AN/AN/A
11/30/2023900,11124,08568154,534N/A
8/31/2023863,22823,824N/AN/AN/A
5/31/2023827,69723,7977,79854,434N/A
2/28/2023802,83122,983N/AN/AN/A
11/30/2022788,29223,209-3,65541,973N/A
8/31/2022772,12723,393N/AN/AN/A
5/31/2022755,41423,155-11,30332,194N/A
2/28/2022743,61222,030N/AN/AN/A
11/30/2021733,38725,329-535,596N/A
8/31/2021726,67225,909N/AN/AN/A
5/31/2021726,42427,1561,81127,875N/A
2/28/2021733,22328,777N/AN/AN/A
11/30/2020723,30925,73628,88250,935N/A
8/31/2020709,06423,876N/AN/AN/A
5/31/2020684,40321,43539,51365,461N/A
2/29/2020653,52720,217N/AN/AN/A
11/30/2019638,03418,951N/A38,209N/A
8/31/2019622,10319,349N/AN/AN/A
5/31/2019611,13719,185N/A34,379N/A
2/28/2019597,71518,966N/AN/AN/A
11/30/2018585,53618,857N/A30,947N/A
8/31/2018572,80717,880N/AN/AN/A
5/31/2018557,99917,633N/A32,586N/A
2/28/2018542,93617,510N/AN/AN/A
11/30/2017526,52317,313N/A35,488N/A
8/31/2017514,88018,239N/AN/AN/A
5/31/2017502,73218,215N/A36,938N/A
2/28/2017490,03715,812N/AN/AN/A
11/30/2016477,73914,981N/A34,300N/A
8/31/2016463,51713,679N/AN/AN/A
5/31/2016447,27312,435N/A30,986N/A
2/29/2016433,32812,738N/AN/AN/A
11/30/2015423,81712,474N/A22,426N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 3349's forecast earnings growth (5.1% per year) is above the savings rate (0.9%).

Earnings vs Market: 3349's earnings (5.1% per year) are forecast to grow slower than the JP market (8.7% per year).

High Growth Earnings: 3349's earnings are forecast to grow, but not significantly.

Revenue vs Market: 3349's revenue (7% per year) is forecast to grow faster than the JP market (6.4% per year).

High Growth Revenue: 3349's revenue (7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 3349's Return on Equity is forecast to be low in 3 years time (10.5%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/11 19:09
End of Day Share Price 2026/09/11 00:00
Earnings2026/05/31
Annual Earnings2026/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

COSMOS Pharmaceutical Corporation is covered by 18 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arashi NishizawaBofA Global Research
Citi ResearchCitigroup Inc
Mitsuru TakayanagiCitigroup Inc